SingleMetabolic & Weight

Pramlintide 5mg

Synthetic amylin analogue evaluated in metabolic models for delayed gastric emptying, postprandial glucose stability, and satiety.

Mechanism

Binds centrally to calcitonin receptor-RAMP complexes to decrease postprandial glucagon secretion, slow gastric emptying, and promote mealtime satiety signaling.

Dosing

Published experimental protocols outline an initial microgram-scale starting dose of 15 mcg administered subcutaneously prior to major feeding events.

Reconstitution

Reconstituting a 5 mg vial with 2.5 mL of bacteriostatic water creates a final solution concentration of 2 mg/mL (2,000 mcg/mL).

Storage

Store unopened lyophilized vials at 2–8°C away from light, and maintain the reconstituted peptide refrigerated without exposure to direct light or sub-freezing conditions.

Mix & measure Pramlintide 5mg

Pre-filled with this protocol's recommended BAC water and documented starting dose — edit any field to run your own numbers.

Mix & measure Pramlintide 5mg

Vial strength → BAC water → target dose

Vial strength

BAC water

Target dose

Concentration2.00mg/mL

Draw volume0.007mL

On the syringe0.750units

Total doses in vial: 333.3

100u80u60u40u20u0

U-100 syringe: 100 units = 1 mL

Reconstitution math only — not dosing advice. U-100 syringe: 100 units = 1 mL. Advanced calculator →

Dosing Chart

Phase / Day(s)	Dose & Frequency	Volume (U-100 units / mL)
Type 1 — start	15 mcg per major meal	~0.75 units (0.0075 mL)
Type 1 — target	30–60 mcg per major meal	1.5–3 units (0.015–0.03 mL)
Type 2 — start	60 mcg per major meal	3 units (0.03 mL)
Type 2 — target	120 mcg per major meal	6 units (0.06 mL)

Reconstitution Steps

1
Thoroughly clean the rubber septums of both the lyophilized peptide vial and the bacteriostatic water container with individual sterile alcohol swabs.
2
Draw 2.5 mL of bacteriostatic water into a sterile mixing syringe.
3
Insert the needle at a slight angle and dispense the diluent down the glass vial wall, avoiding direct forceful contact with the lyophilized cake.
4
Swirl the vial in a gentle circular motion until all peptide solids have dissolved into a clear solution without shaking.
5
Record the date of reconstitution on the label and immediately store the reconstituted vial in a laboratory refrigerator at 2–8°C.

Supplies Needed

Peptide Vial

Lyophilized pramlintide powder (5 mg) requiring reconstitution.

Insulin Syringes (U-100)

Ultra-fine calibrated syringes required for accurate low-volume microgram aliquots.

Bacteriostatic Water

Preserved sterile diluent (2.5 mL required) for peptide dissolution.

Alcohol Swabs

Antiseptic preparation of vial tops and injection contact points.

Why researchers study it

Post-meal glucose control

Body-weight endpoints

Amylin + incretin combinations

Appetite and satiety signaling

These describe what is being studied, not proven benefits, approved uses, or promised results.

Overview

Pramlintide is a laboratory-engineered synthetic analogue of human amylin, an endogenous neuroendocrine hormone produced and released alongside insulin by pancreatic beta cells. In natural human physiology, native amylin readily forms insoluble amyloid fibrils, rendering it unstable for therapeutic and sustained laboratory deployment; pramlintide overcomes this pharmaceutical limitation through targeted proline substitutions that retain native receptor binding capacity while entirely preventing self-aggregation. In preclinical and clinical metabolic modeling, pramlintide is extensively explored for its capacity to blunt postprandial glycemic excursions without directly stimulating insulin release. By mimicking native islet amyloid polypeptide activity within specialized central autonomic networks, it exerts coordinated influence over the rate of nutrient passage from the stomach, suppressive regulation of inappropriate post-meal glucagon secretion, and neurochemical satiety signaling. Investigational protocols frequently evaluate its behavior both as a stand-alone regulator of energy intake and as an experimental co-agent alongside modern incretin mimetics.

References

1.FDA, Prescribing Information, 2015 — SYMLIN (pramlintide acetate) official label and clinical guidelines
2.Ryan et al., Clin Ther, 2005 — Pramlintide pharmacology and proline substitution mechanism in diabetes
3.Whitehouse et al., Diabetes Care, 2002 — 52-week trial of pramlintide as insulin adjunct in type 1 diabetes
4.Hollander et al., Diabetes Care, 2003 — 1-year randomized trial of pramlintide in insulin-treated type 2 diabetes
5.Aronne et al., J Clin Endocrinol Metab, 2007 — Phase 2 dose-escalation of pramlintide for non-diabetic obesity
6.Hay et al., Pharmacol Rev, 2015 — Comprehensive pharmacology and physiology of amylin receptor signaling
7.Enebo et al., Lancet, 2021 — Dual amylin and GLP-1 agonism combining cagrilintide with semaglutide
8.NIDDK / NCBI Bookshelf, LiverTox, 2019 — Clinical summary of pramlintide mechanisms and adverse effects